Brings years of industry, policy, and association leadership experience
WASHINGTON, DC (September 25, 2024) – The Association for Accessible Medicines Board of Directors today announced the appointment of John A. Murphy, III to be the association’s President and Chief Executive Officer. Mr. Murphy will join AAM in October. Mr. Murphy most recently served as the Chief Policy Officer at the Biotechnology Innovation Organization, where he led BIO’s legal, policy, and international initiatives for the organization’s healthcare portfolio.
Keren Haruvi, President of Sandoz North America and Chair of the AAM Board of Directors, stated, “John’s decades-long experience in policy, advocacy, and communications on drugs and biologics makes him the right person to lead our industry’s efforts to advocate for policies to increase patient access to lower-cost generic and biosimilar medicines.”
Prior to BIO, John served as an assistant general counsel at the Pharmaceutical Research and Manufacturers of America, where he provided legal counsel to PhRMA's policy, government affairs, and alliance development teams, advising on U.S. healthcare reform, FDA engagement, and healthcare payment policy. He also previously worked at the law firm Hogan Lovells, LLP, where he advised clients on federal and state healthcare fraud investigations, FDA and CMS regulations, and compliance efforts related to federal and state fraud and abuse laws.
“The generic and biosimilars industry provides over 90% of prescribed medicines, is the backbone of access for many patients, and the key component to addressing health care costs in the US,” said Murphy. “But this critical industry is at risk and is taken for granted by policymakers and the healthcare system in general. I look forward to helping amplify the voice and reach of this industry in Washington as we work hard to ensure affordable medicines remain the critical connector of healthcare and patient health in the US.”
Ms. Haruvi continued, “We are confident that John will lead the association’s talented team to support our work with Congress and the Administration to ensure that the generic and biosimilar industries remain sustainable and patient access to affordable medicine is prioritized. I, along with the entire board, would like to thank David Gaugh for his leadership guiding AAM during our search for a CEO.”
For media inquiries, contact the Communications department at media@accessiblemeds.org.
About AAM
The Association for Accessible Medicines, your generics and biosimilars industry, is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers of finished generic pharmaceuticals and biosimilars, manufacturers of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 13.1 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.